glp-1 receptor agonists and cardiovascular outcome trials an update mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
3 Pre-clinical studies revealed increased insulin levels in primates
Obes Surg 27(2):513521 Peng MG, Gokoffski KK (2021) Updates on recent Developments in Idiopathic Intracranial Hypertension
Acta Pharmacol Sin
At 52 weeks, weight reduction effects were 7.03 kg, 11.07 kg, and 24.15 kg for mono-agonists, dual-agonists, and tri-agonists, respectively
References and more info This post is part of our series on Medicare coverage for cardiovascular health
PMID: 16406191
